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Systemic immunization with soluble flagellin (sFliC) from Salmonella Typhimurium induces
mucosal responses, offering potential as an adjuvant platform for vaccines. Moreover,
this engagement of mucosal immunity is necessary for optimal systemic immunity,
demonstrating an interaction between these two semi-autonomous immune systems.
Although TLR5 and CD103+CD11b+ cDC2 contribute to this process, the relationship
between these is unclear in the early activation of CD4+ T cells and the development
of antigen-specific B cell responses. In this work, we use TLR5-deficient mice and
CD11c-cre.Irf4fl/fl mice (which have reduced numbers of cDC2, particularly intestinal
CD103+CD11b+ cDCs), to address these points by studying the responses concurrently
in the spleen and the mesenteric lymph nodes (MLN). We show that CD103+CD11b+
cDC2 respond rapidly and accumulate in the MLN after immunization with sFliC
in a TLR5-dependent manner. Furthermore, we identify that whilst CD103+CD11b+
cDC2 are essential for the induction of primary T and B cell responses in the
mucosa, they do not play such a central role for the induction of these responses
in the spleen. Additionally, we show the involvement of CD103+CD11b+ cDC2 in
the induction of Th2-associated responses. CD11c-cre.Irf4fl/fl mice showed a reduced
primary FliC-specific Th2-associated IgG1 responses, but enhanced Th1-associated
IgG2c responses. These data expand our current understanding of the mucosal immune
responses promoted by sFliC and highlights the potential of this adjuvant for vaccine
usage by taking advantage of the functionality of mucosal CD103+CD11b+ cDC2.
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INTRODUCTION
The systemic and mucosal immune systems are semi-
autonomous and engaging systemic immunity does not
necessarily induce immunity in mucosal sites. Engaging the
two immune systems concurrently could potentially enhance
the benefits of vaccination, as most vaccines are administered
through subcutaneous (s.c.) or intra-muscular injection. One
antigen that can induce both mucosal and systemic immunity
concurrently after intraperitoneal (i.p.) or s.c. immunization is
purified, soluble flagellin (sFliC) from Salmonella Typhimurium
(1–3). This 51 kDa bacterial motility protein is the only known
ligand for TLR5 (4). Moreover, flagellin is an immunodominant
antigen that can induce robust innate and adaptive immune
responses, which can also be protective (5–7). These properties,
alongside its potential as an adjuvant, mean flagellin is the focus
of multiple vaccine strategies in livestock and in humans (8–12).
The antigenic environment in which flagellin is encountered
influences the type of immune response induced to this protein.
When surface-localized on the bacterium, the antigen-specific
response is Th1-reflecting, whereas to purified flagellin the
response is significantly more Th2-like, including the induction
of FliC-specific IgG1 (13, 14).
Conventional dendritic cells (cDC) are key initiators and
modulators of adaptive immune responses and as such targeting
cDC directly is an approach to enhance responses to vaccines
(15, 16). cDCs can be classified into two major subsets; cDC1
that are require the transcription factors IRF8, BATF3, and ID2,
and cDC2 that development is independent of these transcription
factors, importantly some them require the transcription factor
IRF4 for their survival and function. This classification is
particularly important since it allows the identification of cDCs
equivalents across tissues and even across species (17, 18). In the
intestinal mucosa several sub populations of cDC can be found,
CD103+CD11b−, CD103+CD11b+, and CD103−CD11b+ cDC.
The first corresponds to cDC1 and the latter two to cDC2. Each
of these subsets plays key, non-redundant roles in controlling
immune homeostasis in the intestinal mucosa (19–21).
In vivo studies have shown that by 24 h after i.p. or s.c.
immunization with sFliC, T cell priming is established inmultiple
sites concurrently, including the mesenteric lymph node (MLN),
spleen and peripheral lymph nodes (1). Analysis of cDCs shows
that exclusively in the MLN, there is a rapid TLR5-dependent
accumulation of CD103+ cDC post sFliC-immunization (1).
Moreover, using Cd11c-cre.Irf4fl/fl mice, which have diminished
numbers of CD103+CD11b+ cDCs in the small intestine lamina
propria and a 90% reduction of this population in the MLN, we
showed that this subset was essential for the induction of adaptive
immune responses in the MLN, while splenic cDC2 play only a
partial role. For clarity, CD103+CD11b+ cDCs will be referred
to throughout as CD103+cDC2 (3). This indicates that i.p.,
immunization with sFliC can bridge both systemic and mucosal
Abbreviations: Ab, antibody; cDCs, conventional dendritic cells; GC, germinal
center; i. p., intraperitoneal; MLN, mesenteric lymph node; s.c., subcutaneous;
sFliC, soluble flagellin.
immune systems through the targeting of a single mucosal cDC
subset.
Our previous work examining the role of CD103+cDC2
in regulating the response to sFliC focused on the long-term
antibody response in vivo using the Cd11c-cre.Irf4fl/fl mice.
This necessitated the use of a prime-boost system and did
not focus on the primary T and B cell responses. Whilst all
elements of the response were lost in the MLN when mucosal
CD103+cDC2 were reduced, some features of the anti-FliC
response were retained in the spleen. This could be because some
T and B cell responses were generated in the MLN shortly after
immunization, which could lead to the generation of memory T
and B cell responses that contribute to the responses observed
after secondary immunization. Alternatively, it could be that
cDC2 and cDC1 contributed differentially to the anti-sFliC
response in the MLN and spleen. Therefore, we examine here
the development of the anti-sFliC response in the first days after
immunization to characterize the relationship between cDC2 and
TLR5 and the early induction of IgG switching.
MATERIAL AND METHODS
Mice
Cd11c-cre.Irf4fl/f (19) and NAIP5−/− mice were maintained at
the Biomedical Center at Lund University. Specific pathogen-
free 8 week C57BL/6 mice were purchased from Harlan
Sprague-Dawley. TLR5−/− mice were maintained in-house at
the Biomedical Service Unit at the University of Birmingham.
Littermates or age matched mice were used for all experiments.
All animal procedures were carried out in strict accordance with
the Lund/Malmö Animal Ethics Committee, the University of
Birmingham Ethics Committee and were covered under the UK
Home Office Project license 30/2850.
Antigen Preparation and Immunization
sFliC was generated as described (22), a his-tagged recombinant
protein and purified by nickel affinity chromatography and
immunoprecipitation with a FliC-specific monoclonal. Mice
were immunized i.p. with 20 µg recombinant sFliC for 24 h or
7 days as indicated.
Cell Isolation and Flow Cytometry
Single cell suspensions from spleens and MLNs were generated
by mechanical disruption. When evaluating cDCs, enzymatic
digestion was performed using collagenase VIII digestion (400
U/ml; 25min; 37◦C). Cells were processed for flow cytometry
using previously described procedures (1). Data acquisition was
performed on a LSRII (BD Bioscience) or a CyAnADP (Beckman
Coulter) and analyzed using FlowJo software 9.8.2. (Tree Star).
The following FITC-conjugated antibodies were used, CD3
(145-2C11), B220 (RA3-6B2), and NK1,1 (PK136; all from
eBioscience). The following PE-conjugated antibodies were used;
CD103 (M290) and CD62L (MEL-14; both from eBioscience).
CD11c (N418), CD44 (IM7), and CD95 (MFL3; all from
eBioscience) were PE-Cy7-conjugated. CD11b (M1/70), CD4
(RM4-5, both BD Biosciences), TCRβ (H57-597, Biolegend), GL7
(eBioscience) were PB-conjugated. MHC-II (M5/114.15.2) and
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Streptavidin (eBioscience) APC-conjugated where used. B220
(RA3-6B2), CD11b (MI-70), CD11c (N418) and NK1.1 (PK136;
all from eBioscience) were Alexa700-conjugated. TCRβ (H57-
597, Biolegend) was APC Cy7-conjugated. CD8α (5H10) from
Invitrogen was used PO-conjugated.
cDCswere gated as Lin−[CD3,B220,NK1.1,GR1]CD11c+MHChi
cells, splenic cDC1 were defined as CD8α+ and cDC2
as CD11b+CD4+ cells, mucosal cDC1 were defined as
CD103+CD11b− and cDC2 as CD103+CD11b+ cells. Activated
CD4+ T cells were gated as CD3+CD4+CD44+CD62L−.
Germinal center (GC) B cells were defined as
TCRβ−CD19+GL7+CD95+ cells.
Immunohistochemistry and Confocal
Microscopy
Immunohistochemistry was performed as described previously
(13). Cryosections (6µm) were incubated with primary
unlabelled Abs for 45min at RT before addition of either
HRP-conjugated or biotin-conjugated secondary antibodies.
FliC-binding cells were identified as described (1) using soluble
biotinylated FliC. Subsequently streptavidin ABComplex
alkaline phosphatase (Dako) was used. Signal was detected
using diaminobenzidine for HRP activity and naphthol
AS-MX phosphate with Fast Blue salt and levamisole for
alkaline phosphatase activity. Images were acquired using
a Leica microscope DM6000 using 10x and 20x objectives.
Quantification of sFliC+IgG1+ and sFliC+IgG2c+ was
performed in two independent experiments, each with 4
mice per group. A total of 10 random fields were evaluated per
slide.
Immunofluorescence was performed on frozen sections.
Staining was performed in PBS containing 10% FCS, 0.1%
sodium azide and sections were mounted in 2.5% 1,4-
Diazabicyclo(2,2,2)octane (pH 8.6) in 90% glycerol in PBS.
After incubation with primary Abs (1 h, room temperature),
secondary Abs were added (30min; room temperature). Images
were acquired using the Fluorescence Zeiss Axio Scan.Z1, image
analysis was performed with Zen, 2012 blue edition.
The following Abs were used for immunofluorescence:
CD11c, Dec205, CD103. DCIR2 was used biotinylated. CD11b
(eBioscience) and streptavidin (Jackson Immunoresearch)
were used A488 conjugated. And AMCA-conjugated anti-IgM
(Jackson Immunoresearch) was used. The following Abs were
used for immunohistochemistry: IgD, IgG1, and IgG2c. sFliC
and PNA (Vector) biotinylated were used.
In vitro Restimulation for the Detection of
Antigen-Specific CD4+ T Cells
Antigen-specific CD4+ T cells were detected by their expression
of CD154 post-restimulation as previously described (23). In
brief, 6 × 106 cells (from spleen or MLN) were cultured in
the presence of sFliC (5µg/ml), anti-CD40 (1C10 2µg/ml),
biotinylated anti-CD154 (MR1 5µg/ml) and anti-Fcγ receptor
(2.4G2 50µg/ml) for 48 h. Control wells included cells cultured
without antigen. The expression of CD154 was evaluated by
staining the cells with Streptavidin-APC and gating was done on
Lin−(CD19/CD11b/NK1.1/CD11c)TCRβ+CD4+CD62L−.
Sflic-Specific ELISA
ELISA plates were coated with 5µg/ml of sFliC (24 h at 4◦C) and
blocked with 1% BSA overnight at 4◦C. Serum was diluted 1:100
in PBS−0.05% Tween, and was further diluted stepwise. Plates
were incubated for 1 h at 37◦C. Bound antibodies were detected
using alkaline phosphatase conjugated, goat anti-mouse IgG,
IgG1, and IgG2c Abs (Southern Biotech). Alkaline phosphatase
activity was detected using Sigma-Fast p-nitrophenylphosphate
(Sigma Aldrich). Relative reciprocal titers were calculated by
measuring the dilution at which the serum reached a defined
OD405.
Statistics
For statistics we used the non-parametric Mann-Whitney sum
of ranks test or two-way ANOVA as appropriate using the
GraphPad Prism software (GraphPad).
RESULTS
The Accumulation of CD103+cDC2 in the
MLN After sFliC Immunization Is
TLR5-Dependent
Intraperitoneal immunization of sFliC induces a rapid MyD88-
dependent accumulation of intestinal-derived CD103+cDC2 in
the MLN (1, 3). To analyse the role of TLR5 in this response,
WT and TLR5−/− mice were immunized with sFliC and the
cDC response analyzed by flow cytometry and in situ by
immunofluorescence 24 h post-immunization. In the MLN of
WT mice, immunization with sFliC resulted in an increase in
the frequency and absolute numbers of CD103+cDC2, which
was abrogated in TLR5−/− mice, no significant change in
absolute numbers or frequency was observed for cDC1 or
CD103−cDC2 (Figure 1A). Immunofluorescence microscopy
showed that CD103+cDC2 were mainly located in the T zone,
before and after immunization, although they were less abundant
in the absence of immunization. The high zoom-insets confirmed
that CD103+cDC2 in the T zone express CD11c, CD103, and
CD11b. TLR5 is the extracellular receptor for sFliC, however
there is an intracellular pathway for flagellin detection controlled
by NAIP5 (24). To evaluate the contribution of this alternative
pathway we evaluated the CD103+cDC2 in NAIP5−/− mice, we
observed a similar accumulation of those cells in comparison
with the WT after sFliC immunization, strongly suggesting that
TLR5 exclusively controls the response to sFliC by CD103+cDC2
in the MLN (Figure 1B).
In contrast to the MLN, in the spleen there was no change
in the frequency and absolute numbers of cDC2 (identified
as CD11b+ cDC) of WT mice after immunization with sFliC
(Figure 1C). Furthermore, no difference was observed in the
location of cDC2 (DCIR2+) which remain primarily localized
in the bridging channels between the red and white pulps (25).
Loss of TLR5 did not alter the numbers of cDC2 before or
after immunization, nor the distribution of these cells within the
spleen (Figure 1B). Therefore, immunization with sFliC results
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FIGURE 1 | Mucosal CD103+cDC2 respond to sFliC immunization in a TLR5-dependent manner. Wild-type (WT) or TLR5−/− mice were immunized i.p. with sFliC
and cDCs (Lin−MHC-IIhiCD11chi) were evaluated 24 h later, alongside non-immunized (N.I.) mice. (A) MLN representative flow cytometry plots (including percentages)
of cDC1 (Lin−MHC-IIhiCD11chiCD11b−CD103+), CD103+cDC2s (Lin−MHC-IIhiCD11chiCD11b+CD103+) and CD103−cDC2 (Lin−MHC-IIhiCD11chiCD103−) are
shown with adjacent graphs of absolute numbers. Representative photomicrographs of MLN sections stained for CD11c; blue, CD103; red, CD11b; green, and IgM;
white (scale bar = 200µm) are shown (top right). Zoom-in insets (white boxes) show single staining and a merge of CD11c, CD103, and CD11b (scale bar = 20µm).
(Continued)
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FIGURE 1 | T, T zone; B, B zone. (B)WT or NAIP5−/− mice were immunized i.p., with sFliC and absolute numbers of MLN CD103+cDC2s were evaluated 24 h later,
alongside non-immunized (N.I.) mice. (C) Wild-type (WT) or TLR5−/− mice were immunized i.p. with sFliC and splenic cDCs (Lin−MHC-IIhiCD11chi) were evaluated
24 h later, alongside non-immunized (N.I.) mice. Representative flow cytometry plots (including percentages) of cDC2s (Lin−MHC-IIhiCD11chiCD11b+) are shown with
adjacent graphs of absolute numbers. Representative photomicrographs of spleen sections stained for CD11c; blue, Dec205; green, DCIR2; red, and IgM; white
(scale bar = 100µm). Zoom-in insets (white boxes) show the differential location of cDC1s (Dec205+) in the T zone and cDC2s (DCIR2+) in the bridging channels.
Data shown as mean+s.d. of 4 mice and are representative of 3 independent experiments. **P < 0.001, by two-way analysis of variance (ANOVA) N.S., not significant.
FIGURE 2 | The primary T cell response to sFliC is dependent upon CD103+cDC2 in the mucosa but not in the spleen. cDC populations in Irf4fl/fl or
Cd11c-cre.Irf4fl/fl mice were evaluated in (A) MLN and (B) spleen. Irf4fl/fl or Cd11c-cre.Irf4fl/fl mice were either non-immunized (N.I.) or immunized with sFliC and T
cell responses were evaluated 7 days later. Representative flow cytometry plots (percentages) and absolute numbers (graphs) of activated CD4+ T cells
(CD3+CD4+CD44+CD62L−) in the (C) MLN and (D) spleen. Ex vivo sFliC-specific restimulations, single cell suspensions were restimulated with 5µg/ml of sFliC in
the presence of anti-CD40 (2µg/ml), biotinylated anti-CD154 (5µg/ml) for 48 h. Antigen-specific CD4+ T cells were identified by detection of the anti-CD154 by
streptavidin. (E) MLN and (F) spleen representative flow cytometry plots (percentages) and absolute numbers (graphs) of CD154+ CD4+ T cells. Data shown as
mean + s.d. (n = 4 mice/group) representative experiment of 3 performed. **P < 0.001; *P < 0.05, by two-way analysis of variance (ANOVA), N.S., not significant.
in the selective accumulation of CD103+cDC2 in the MLN, but
not in the spleen in a TLR5 dependent manner.
CD103+cDC2 Are Essential for T Cell
Priming in the MLN After Immunization
With sFliC
To assess the contribution of cDC2 to T cell priming after
immunization with sFliC, we assessed responses in Cd11c-
cre.Irf4fl/fl mice. These mice lack IRF4 in cells that express
CD11c, resulting in a 50% reduction of CD103+CD11b+ cDCs
in the small intestine lamina propria and a 90% reduction in the
MLN (19). Figure 2A shows the significant reduction of MLN
CD103+CD11b+ cDCs in Cd11c-cre.Irf4fl/fl mice in comparison
with the Irf4fl/fl mice. Furthermore, we also show the expected
reduction of splenic cDC2 in these mice (Figure 2B). The
frequency and number of activated CD4+ T cells in the MLN of
Cd11c-cre.Irf4fl/fl mice 7 days after FliC immunization, was lower
compared to Irf4fl/fl mice and similar to non-immunized mice
(Figure 2C). In contrast, absolute numbers of activated CD4+
T cells in the spleen were similar between Cd11c-cre.Irf4fl/fl and
Irf4fl/fl mice (Figure 2D). To examine the endogenous antigen-
specific T cell response we performed an in vitro re-stimulation
essay that uses the transient expression of CD154 to identify
antigen-specific CD4+ T cells (23). In the MLN from immunized
Cd11c-cre.Irf4fl/fl mice, the frequency and number of CD154+
sFliC-specific CD4+ T cells was significantly lower than those in
immunized Irf4fl/fl mice and similar to levels observed in from
non-immunized mice (Figure 2E). In contrast, in the spleen an
increase of CD154+ sFliC-specific CD4+ T cells was observed
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FIGURE 3 | The generation of primary B cell responses to sFliC in the MLN,
but not the spleen, are dependent upon CD103+cDC2. Irf4fl/fl or
Cd11c-cre.Irf4fl/fl mice were either non-immunized (N.I.) sFliC-immunized and
GC B cells (TCRβ−CD19+GL7+CD95+) were evaluated 7 days later. (A) MLN
and (B) spleen representative flow cytometry plots (percentages) and absolute
numbers (graphs) of GC B cells. Data are mean+s.d. (n = 4 mice/group)
representative experiment of 3 performed. **P < 0.001; *P < 0.05, by
two-way analysis of variance (ANOVA), NS, not significant. (C) Serum
anti-sFliC IgG, IgG1, and IgG2c evaluated by enzyme-linked immunosorbent
assay (ELISA). Data shown as mean + s.d. (n = 12 mice/group) and shows
three independent experiments pooled together. *P < 0.05, two-way analysis
of variance (ANOVA), N.S., not significant.
in the Cd11c-cre.Irf4fl/fl mice compared to the non-immunized
mice but it was significantly lower compared to Irf4fl/fl mice
(Figure 2F). Collectively, these results demonstrate that the early
T cell response induced to sFliC is dependent on mucosal
CD103+cDC2s, however in the spleen IRF4 expression by cDCs
only impacts partially on T cell priming.
cDC2 Influence the Extent and Direction of
IgG Switching
In order to address how the B cell response to sFliC is affected
in the Cd11c-cre.Irf4fl/fl mice we analyzed GC B cells by flow
cytometry 7-days post-immunization. In the MLN, Cd11c-
cre.Irf4fl/fl mice showed no increase in the number of GC B cells
in comparison to non-immunized and Irf4fl/fl sFliC-immunized
mice (Figure 3A). In contrast, in the spleen, immunized Cd11c-
cre.Irf4fl/fl and Irf4fl/fl mice displayed a similar increase in GC
B cell numbers (Figure 3B). To analyse the FliC-specific Ab
response in more detail, serum Ab titres were evaluated by
ELISA. Total sFliC-specific IgG titers were reduced in Cd11c-
cre.Irf4fl/fl mice in comparison with Irf4fl/fl mice (Figure 3C).
In mice, sFliC induces some Th2-associated features including
antigen-specific IgG1 (13, 14). FliC-specific IgG1 was detected
in sFliC-immunized Irf4fl/fl mice, but was absent in Cd11c-
cre.Irf4fl/fl mice (Figure 3D). This was unexpected since some
sFliC-specific IgG was detected in Cd11c-cre.Irf4fl/fl mice and so
titers of Th1-associated IgG2c were assessed. This isotype was
detected exclusively in sFliC-immunized Cd11c-cre.Irf4fl/fl mice
(Figure 3E), suggesting that cDC2 contribute to IgG1 switching.
We hypothesized that the serum IgG2c derived from
spleen. To analyze this possibility in situ, we performed
immunohistochemistry on serial sections from the MLN and
spleen of sFliC-immunized Irf4fl/fl and Cd11c-cre.Irf4fl/fl mice.
GCs were identified as follicular areas that bind PNA and
sFliC-specific cells were identified by using biotinylated sFliC
in conjunction with either anti-IgG1 or anti-IgG2c Abs. In the
MLN, sFliC-specific cells were exclusively observed in Irf4fl/fl
mice and were IgG1+ (Figure 4A). In contrast, sFliC-binding
cells were found in the spleens of both Irf4fl/fl and Cd11c-
cre.Irf4fl/fl mice whilst in the Irf4fl/fl mice, the sFliC-specific
cells were IgG1+ and IgG2c−. In contrast, in Cd11c-cre.Irf4fl/fl
mice the sFliC-specific cells were exclusively IgG2c+ (Figure 4B).
Collectively, these results show that cDC2s play a role in the
polarization of the Ab response in vivo.
DISCUSSION
We have previously shown that sFliC can drive a long-term
mucosal adaptive response after i.p. immunization (1, 3).
Furthermore, we also have shown that s.c. and i.p. immunization
both induce similar cDC and IgA responses in the MLN,
suggesting that our observations are not dependent of the
route of immunization, but due to the intrinsic properties of
sFliC. When addressing the prime-boost immune response in
Cd11c-cre.Irf4fl/fl mice the immune response to sFliC in the
spleen was reduced, but not abrogated, suggesting the possibility
that memory cells could contribute to the response. To address
this possibility we studied the primary immune response to
sFliC and show that the primary T and B cell responses to sFliC
in the MLN are completely dependent on CD103+cDC2,
while that in the spleen is only partially dependent
on cDC2.
Mucosal CD103+cDC2s are probably more efficient at driving
responses after sFliC immunization because of their high
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FIGURE 4 | Switching to IgG1 is abrogated in the CD11c-cre.Irf4fl/fl mice. Irf4fl/fl or Cd11c-cre.Irf4fl/fl mice were sFliC-immunized for 7 days. (A) Representative
photomicrographs of serial sections from MLN and spleen stained for: PNA-binding cells (blue) and IgD-expressing cells (brown) (first column) or sFliC-binding cells
(blue) and IgD-expressing cells (brown) (second column), scale bar = 200µm. The third and fourth columns show zoom-in insets (black-boxed areas) stained to
detect sFliC-binding cells and IgG1 and IgG2c respectively (scale bar = 50µm). T, T zone; B, B zone. (B) Quantification of sFliC+ IgG1+ cells and sFliC+ IgG2c+ cells
in the MLN and spleen. A total of 10 random fields were evaluated per slide. Data shown as mean + s.d. (n = 8 mice pooled from two independent experiments). ***P
< 0.0001, by Mann-Whitney. N.D. non-detected.
expression levels of TLR5 in comparison to splenic cDCs (26, 27).
TLR5 can play an additional role in enhancing antigen capture
and presentation through MHC-II and this is not MyD88-
dependent (28). Moreover, ligation of TLR5 itself will lead
to an upregulation of co-stimulatory molecules and cytokine
expression, in a MyD88-dependent manner (4, 14). This is
likely to be the mechanism that mediates the accumulation of
CD103+cDC2 into the MLN after immunization with sFliC
(1, 3). Furthermore, splenic cDCs are able to respond rapidly after
sFliC immunization, possibly through activation by a bystander
effect (22, 29). Therefore, in the spleen there may be less of a
selective advantage for one subset to capture sFliC over another,
meaning that both cDC1 and cDC2 are potentially able to present
antigen to CD4+ T cells and initiate priming. In support of this
idea ex vivo data using sorted, in vivo loaded, cDCs showed
that both splenic cDC1 and cDC2 are able to mediate to T cell
priming. Additionally, when flagellin is used as an adjuvant in
studies using DEC205 and 33D1 to target splenic cDC1 and
cDC2 cells, it shows that the presence of flagellin enhances the
capacity of both cDC subsets to mediate T cell proliferation (30).
This demonstrates that flagellin can promote responses in both
cDC subsets, which indirectly supports our findings. In contrast
to this, in the intestinal mucosa only CD103+cDC2 mediate T
cell priming (3). Therefore, despite having a similar ontogeny,
mucosal CD103+cDC2 and splenic cDC2 show differences in
their capacity to capture sFliC and this differencemay account for
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why cDC2 play such a dominant role in driving T cell responses
to FliC in the MLN but not the spleen.
After primary immunization of WT mice with sFliC, there is
a robust GC response in the spleen, but a limited extrafollicular
plasma cell response (13, 22). The predominant antigen-specific
IgG isotype detected after immunization with sFliC in the serum
is IgG1, associated to a Th2-like response (13, 14). Importantly,
in the Cd11c-cre.Irf4fl/fl mice there was no significant increase
in numbers of GC B cells in the MLN. In contrast, in the
spleen, there was a normal GC response, which suggested that
a B cell response developed in the spleen but not in the MLN
when CD103+cDC2 were reduced. Nevertheless, there were
lower serum total IgG titers in the CD11-cre.Irf4fl/fl mice and an
abrogated IgG response in the BM (3). One interpretation of this
is that in the primary response to sFliC, the antibody response
generated in the MLN is a significant, if not predominant,
contributor, to the serum total FliC-specific IgG pool.
Amore detailed analysis of the IgG response showed that there
was a difference in the predominant IgG isotype induced between
immunized Cd11c-cre.Irf4fl/fl and Irf4fl/fl mice. Inducing the
appropriate IgG isotype is important as the distinct IgG isotypes
can influence the level of protection afforded by vaccination (31)
or against different pathogens (32). Surprisingly, the residual
FliC-specific IgG response observed in Cd11c-cre.Irf4fl/fl mice
was not of the IgG1 isotype, but instead was of the IgG2c
isotype. Immunohistochemistry showed that the FliC-specific
IgG2c was being produced locally in the spleen by cells proximal
to GC (Figure 3). This suggests that although a B cell response
is maintained in the spleens of the Cd11c-cre.Irf4fl/fl mice, this
B cell response is substantially different qualitatively. Further
work is needed to identify what B cell associated factors, such as
BAFF or APRIL, cDC1 and cDC2 produce that may contribute
to this and whether these differ between cDCs from different
anatomical sites. In mice, there is a partial association between
the direction of the T helper response and IgG isotype switching
and so these findings may suggest that cDC2 contribute to Th2-
associated responses. An association between cDC2 and Th2
polarization has been described previously in the context of
infection or in atopic asthma models (21, 33–35). Moreover, we
are working toward developing strategies to conjugate sFliC to
different antigens and evaluate if these features that sFliC is able
to promote as an adjuvant can be transferred to clinically relevant
antigens. Our data helps inform on the relativemerits of targeting
specific DC populations in vaccination strategies.
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